In April 2024, the FDA granted accelerated approval for T-DXd in adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors, including NSCLC, who have received prior systemic therapy and lack satisfactory alternatives. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.